Affinage

Showing FKBP4 — FKBP52 is a alias.

FKBP4

Peptidyl-prolyl cis-trans isomerase FKBP4 · UniProt Q02790

Length
459 aa
Mass
51.8 kDa
Annotated
2026-06-09
100 papers in source corpus 53 papers cited in narrative 53 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/7 claims corpus-supported (86%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

FKBP4 (FKBP52) is an Hsp90-associated immunophilin co-chaperone that uses functionally separable domains to potentiate steroid hormone receptor signaling and to couple chaperone clients to microtubule-based transport (PMID:1279700, PMID:12606580). It possesses FK506/rapamycin-sensitive peptidyl-prolyl isomerase (PPIase) activity confined to its N-terminal FK1 domain, while a C-terminal TPR domain binds the Hsp90 C-terminal EEVD motif in an ATP-independent manner (PMID:1279700, PMID:8216288, PMID:7526392, PMID:11473108). Within unactivated glucocorticoid, progesterone, androgen, and mineralocorticoid receptor heterocomplexes, hormone binding triggers exchange of the antagonistic co-chaperone FKBP51 for FKBP52, which recruits cytoplasmic dynein/dynactin via its PPIase domain to drive retrograde microtubule-dependent transport of the intact receptor-Hsp90 complex to the nucleus (PMID:10601253, PMID:11278753, PMID:11751894, PMID:20038533). FKBP52 potentiates receptor activity by increasing hormone-binding affinity, a function genetically dissected to the proline-rich FK1 loop (Pro119) rather than catalytic isomerization, and is essential in vivo for progesterone-dependent uterine implantation and androgen receptor signaling in male reproductive tissues (PMID:12606580, PMID:16176985, PMID:15831525, PMID:17142810, PMID:17938211). Beyond receptors, FKBP52 gates Ca2+ channels through proline isomerization (stimulus-dependent TRPC1 opening in axon guidance; inhibition of TRPV5) (PMID:16352746, PMID:19945390), binds tubulin and Tau to modulate microtubule dynamics and drive PPIase-independent Tau oligomerization with prion-like seeding linked to tauopathy (PMID:17435176, PMID:20133804, PMID:25888602, PMID:26903089, PMID:33832539), stabilizes Argonaute2 to promote RISC assembly (PMID:24049110, PMID:23741051), and activates NF-κB/IKK signaling (PMID:25104352, PMID:34112753). Its Hsp90 binding is switched off by casein kinase II phosphorylation of Thr-143 (PMID:9405642). FKBP52 also mediates the neuroregenerative action of FK506 after spinal cord injury, in opposition to FKBP51 (PMID:32828804).

Mechanistic history

Synthesis pass · year-by-year structured walk · 19 steps
  1. 1992 High

    Establishing that FKBP52 is an enzyme and a chaperone-associated factor defined its dual identity as an immunophilin that physically partners Hsp90 in steroid receptor complexes.

    Evidence Recombinant PPIase assay with FK506/rapamycin inhibition and co-IP with hsp90

    PMID:1279700

    Open questions at the time
    • Did not map which domain bound Hsp90 versus which carried catalytic activity
    • Functional consequence for receptor activity unknown
  2. 1993 High

    Domain mapping resolved the modular architecture, assigning PPIase activity to the N-terminal FKBP12-like domain and protein-interaction roles to a separate TPR region.

    Evidence E. coli deletion-mutant PPIase assays plus TPR identification from receptor complexes; in vitro GR complex reconstitution

    PMID:8216288 PMID:8341706 PMID:8514757

    Open questions at the time
    • TPR-Hsp90 binding was inferred, not yet directly demonstrated
    • ATP-binding functional role unresolved
  3. 1994 High

    Direct mapping showed the C-terminal TPR domain mediates ATP-independent, immunosuppressant-insensitive Hsp90 binding, confirming chaperone docking is independent of the catalytic site.

    Evidence Gel-retardation with purified proteins and deletion mutants

    PMID:7526392

    Open questions at the time
    • Required flanking residues beyond core TPR not yet defined
    • Stoichiometry on Hsp90 dimer unknown
  4. 1996 Medium

    Competition among TPR immunophilins for Hsp90 established that FKBP52, CyP40 and others form mutually exclusive heterocomplexes, framing combinatorial chaperone assembly.

    Evidence GST-fusion deletion pulldowns and competition with myometrial cytosol; NMR structure of FK1 domain

    PMID:8621687 PMID:8780506

    Open questions at the time
    • TPR alone insufficient; flanking acidic/basic determinants only partially defined
    • Functional outcome of exclusivity not tested
  5. 1997 High

    Identification of CK2 phosphorylation at Thr-143 that abolishes Hsp90 binding revealed a post-translational switch controlling chaperone complex composition.

    Evidence In vitro CK2 kinase assay, mutagenesis mapping, in vivo 32P labeling, Hsp90 binding assay

    PMID:9405642

    Open questions at the time
    • Physiological signals driving Thr-143 phosphorylation unknown
    • Downstream effect on receptor transport untested
  6. 1999 High

    Demonstrating that the PPIase domain binds cytoplasmic dynein provided the physical link connecting receptor-Hsp90 complexes to the motor machinery.

    Evidence Cross-linking of purified proteins, co-immunoadsorption, domain-fragment competition; stoichiometry of one FKBP52 per Hsp90 dimer

    PMID:10601253 PMID:11350175

    Open questions at the time
    • Direct demonstration of transport in cells not yet shown
    • Dynein adaptor subunit contacted not identified
  7. 2001 High

    Live-imaging and biochemical work established that FKBP52 drives hormone-induced retrograde microtubule transport of GR and that hormone triggers FKBP51-to-FKBP52 exchange with dynein recruitment.

    Evidence GFP-GR live imaging, microtubule disruption, fractionation and co-IP in hormone-treated cells; chaperone-domain and PPIase/TPR mutant analyses; Drosophila TRPL channel patch-clamp

    PMID:11278753 PMID:11350175 PMID:11473108 PMID:11514552 PMID:11751894

    Open questions at the time
    • Whether transport is required for transactivation versus affinity not separated
    • Nuclear pore transit mechanism not resolved
  8. 2003 High

    Yeast genetics showed FKBP52 uniquely potentiates GR transactivation by raising hormone-binding affinity, requiring both Hsp90 binding and (at this stage) PPIase activity.

    Evidence S. cerevisiae reporter assays with PPIase-dead and TPR-dead mutants; hormone-binding affinity measurement

    PMID:12606580 PMID:12611898

    Open questions at the time
    • Catalytic mechanism of affinity enhancement not defined
    • Whether other receptors behave identically not yet tested
  9. 2005 High

    Knockout mice established tissue-specific physiological roles, showing FKBP52 is essential for PR-dependent uterine implantation and AR signaling in male reproductive tissue.

    Evidence Fkbp52-knockout mice with hormone-binding, reporter, ChIP and gene-expression readouts; TRPV5 patch-clamp/Co-IP

    PMID:15831525 PMID:16176985 PMID:16352746

    Open questions at the time
    • Why receptor dependence is tissue-restricted not explained
    • Step controlled downstream of receptor not yet localized
  10. 2006 High

    ChIP in knockout cells localized FKBP52's action to a step downstream of AR DNA binding, refining the model from chromatin loading to transactivation competence.

    Evidence Fkbp52-knockout MEFs, reporter assays, ChIP showing normal promoter occupancy, hormone binding; AAV dynein-trafficking knockout/rescue

    PMID:16828834 PMID:17142810

    Open questions at the time
    • Molecular nature of the downstream transactivation step undefined
    • Generalization to endogenous AR targets limited
  11. 2007 High

    An unbiased screen identified FK1-loop Pro119 as the determinant distinguishing FKBP52 from FKBP51 and showed potentiation is independent of PPIase catalysis, redefining the active surface.

    Evidence Yeast random-mutagenesis screen of FKBP51, reciprocal mutagenesis, mammalian reporter assays with catalytic-dead mutants; tubulin binding/depolymerization mapping

    PMID:17435176 PMID:17938211

    Open questions at the time
    • How the Pro119 loop contacts the receptor structurally unresolved
    • Reconciliation with earlier PPIase-dependence claims incomplete
  12. 2009 High

    Reconstitution of the MR-Hsp90-dynein/dynactin transport module generalized the FKBP52-driven retrograde transport mechanism across steroid receptor classes.

    Evidence Fractionation, cross-linking, and motor-complex reassembly on stripped MR immune pellets; TRPC1 isomerization-gated axon guidance in vivo

    PMID:19945390 PMID:20038533

    Open questions at the time
    • Quantitative contribution of transport to nuclear signaling not measured
    • Channel-gating versus receptor roles use overlapping domains, leaving substrate specificity open
  13. 2010 High

    Direct Tau binding and antagonism of Tau-driven microtubule assembly placed FKBP52 in neuronal cytoskeletal and tauopathy biology.

    Evidence Purified-protein binding, microtubule assembly assay, neurite-length quantification in PC12 cells, co-localization in cortical neurons; APP/Atox1-copper interaction in Drosophila; RET51 phospho-Y905 dependent Co-IP

    PMID:20084280 PMID:20133804 PMID:20442138

    Open questions at the time
    • Relationship between Tau binding and steroid co-chaperone roles unclear
    • In vivo pathological relevance not yet established at this stage
  14. 2014 High

    Demonstration that FKBP52 induces pathological Tau oligomers/filaments with prion-like seeding, including in vivo zebrafish rescue, advanced a causative role in Tau aggregation.

    Evidence Purified-protein assembly with EM, seeding in neuroblastoma cells, Tau-P301L zebrafish knockdown; FK1-GR interaction by BiFC/PLA in glioblastoma

    PMID:24623856 PMID:25132599 PMID:25888602

    Open questions at the time
    • Cellular trigger converting FKBP52 from chaperone to aggregation factor unknown
    • Relationship to Hsp90 chaperone cycle not defined
  15. 2016 High

    Mapping the Tau interaction to the FK1/FK2 surface and showing PPIase-independence consolidated a catalysis-independent aggregation mechanism, while parallel work extended dynein-coupled transport to hTERT.

    Evidence PPIase-dead oligomerization assay, NMR mapping of PHF6 peptide; Co-IP mapping of TPR-Hsp90 and PPIase-dynamitin for hTERT transport with telomerase readouts

    PMID:26903089 PMID:27503910

    Open questions at the time
    • Structural basis of PHF6-FK1/FK2 engagement at atomic level incomplete
    • hTERT findings rest on single-lab Co-IP/depletion
  16. 2013 Medium

    Identification of FKBP52/p23 association with Argonaute2 extended its co-chaperone role to RISC assembly and small-RNA silencing.

    Evidence Co-IP, siRNA depletion, FK506 inhibition, miRNA/luciferase reporter assays, lysosome-inhibitor rescue

    PMID:23741051 PMID:24049110

    Open questions at the time
    • Whether FKBP52 acts catalytically on Ago2 or only via Hsp90 cycle unclear
    • Single-lab Co-IP evidence
  17. 2014 High

    FKBP52 was shown to drive NF-κB activation through PPIase- and TPR-dependent RelA nuclear retention and FKBP51-to-FKBP52 exchange, paralleling the steroid receptor switch.

    Evidence Reporter, Co-IP, EMSA, ChIP, siRNA with domain/PPIase mutants

    PMID:25104352

    Open questions at the time
    • Hsp90-independence of this role contrasts with receptor mechanism
    • Physiological NF-κB target context limited
  18. 2019 Medium

    Proximity proteomics and cancer models linked FKBP4 to PI3K/Akt/mTOR signaling and to IKK assembly, broadening its oncogenic signaling roles.

    Evidence BioID interactome, siRNA knockdown, xenografts; Co-IP domain mapping of Hsp90/IKK with kinase assays

    PMID:31660083 PMID:34112753

    Open questions at the time
    • Direct versus proximity interactions not distinguished for PI3K components
    • Single-lab evidence for each pathway
  19. 2021 Medium

    Genetic epistasis with FK506 established that FKBP52, opposed by FKBP51, mediates neuroregenerative recovery, and additional work tied FKBP51/52 to AR dimerization and ERα stabilization via BRCA1.

    Evidence Fkbp52 vs Fkbp51 knockout spinal-cord-injury mice with locomotor readouts; AR dimerization/ChIP assays; FKBP52-BRCA1 Co-IP and ERα stability assays

    PMID:32828804 PMID:33832539 PMID:34057812 PMID:35394865

    Open questions at the time
    • Molecular target of the neurotrophic action not identified
    • AR/ERα roles depend partly on single-lab depletion data

Open questions

Synthesis pass · forward-looking unresolved questions
  • How FKBP52 selects among its many functional outputs—receptor transport, channel gating, Tau aggregation, RISC assembly, NF-κB activation—using a shared, largely PPIase-independent FK1 surface remains unresolved.
  • No structural model of FKBP52 bound to a steroid receptor or to dynein
  • Determinants of client/substrate selectivity unknown
  • Integration of catalysis-independent and chaperone-dependent mechanisms unresolved

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016853 isomerase activity 4 GO:0060090 molecular adaptor activity 4 GO:0098772 molecular function regulator activity 4 GO:0008092 cytoskeletal protein binding 2 GO:0044183 protein folding chaperone 2
Localization
GO:0005634 nucleus 2 GO:0005829 cytosol 2 GO:0005856 cytoskeleton 2 GO:0005815 microtubule organizing center 1
Pathway
R-HSA-162582 Signal Transduction 4 R-HSA-74160 Gene expression (Transcription) 4 R-HSA-392499 Metabolism of proteins 3 R-HSA-9609507 Protein localization 3 R-HSA-8953854 Metabolism of RNA 2
Partners
AGO2BRCA1DYNLL/DYNEINHSP90MAPTRELATRPC1TUBB
Complex memberships
FKBP52-p23-Ago2 (RISC-loading) complexGR-Hsp90-FKBP52-dynein heterocomplexHsp90-FKBP52-HOP/p23 complexMR-Hsp90-FKBP52-dynein/dynactin complex

Evidence

Reading pass · 53 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1992 FKBP52 (FKBP59) possesses peptidyl-prolyl cis-trans isomerase (PPIase) activity inhibited by FK506 and rapamycin, and associates with hsp90 in untransformed mammalian steroid receptor complexes. The immunosuppressant-binding site is distinct from the hsp90-binding site, implying separate structural domains. Recombinant protein expression in E. coli, PPIase enzymatic assay, co-immunoprecipitation with hsp90 Proceedings of the National Academy of Sciences of the United States of America High 1279700
1992 Rabbit FKBP52 (FKBP59-HBI) binds calmodulin in a Ca2+-dependent manner, retained on calmodulin-Sepharose in 2 mM Ca2+ and eluted by EGTA; it is also a substrate for calpain II, a Ca2+-activated protease. Calmodulin-Sepharose affinity chromatography, in vitro proteolysis assay Biochemical and biophysical research communications Medium 1384470
1993 The PPIase activity of FKBP52 (p59-HBI) resides entirely in its N-terminal domain (domain I), which has the highest homology to FKBP12; a second domain (domain II) shows residual enzymatic activity. Overexpression of domain deletion mutants in E. coli, PPIase activity assay Biochemical and biophysical research communications High 8216288
1993 The tetratricopeptide repeat (TPR) domain of FKBP52 (p59, FKBP59) is proposed to mediate protein-protein interactions including hsp90 binding; this was supported by identification of a conserved TPR domain in the estrogen receptor-binding cyclophilin (ERBC/CyP40). Affinity chromatography, sequence homology analysis, protein identification from estrogen receptor complex The Journal of biological chemistry Medium 8514757
1993 Recombinant mouse FKBP52 can be assembled in vitro with the glucocorticoid receptor complex, confirming it is a functional component of the unactivated GR heterocomplex; it also possesses ATP/GTP binding activity stimulated by divalent cations. Baculovirus expression, in vitro assembly assay with glucocorticoid receptor, ATP binding assay Proceedings of the National Academy of Sciences of the United States of America Medium 8341706
1994 The TPR domain located in the C-terminal part of FKBP52 (FKBP59-HBI) is necessary for hsp90 binding; this interaction is ATP-independent and not affected by FK506 or rapamycin. Gel-retardation assay with purified proteins, deletion mutant analysis Proceedings of the National Academy of Sciences of the United States of America High 7526392
1996 FKBP52 competes with cyclophilin 40 (CyP40) for hsp90 binding, leading to mutually exclusive immunophilin-hsp90-receptor complexes; the TPR domain alone is not sufficient for stable hsp90 association—flanking acidic and basic residues are also required. GST-fusion deletion mutant pulldown, competition assay with myometrial cytosol The Journal of biological chemistry Medium 8621687
1996 NMR structure of the N-terminal immunophilin domain of FKBP52 (FKBP59-I, residues 1–149) was determined; it adopts a twisted antiparallel beta-sheet and short alpha-helix, globally similar to FKBP12, with an unusual Trp89–Phe129 hydrogen bond important for immunosuppressant binding. Multidimensional NMR spectroscopy, distance geometry, molecular dynamics Biochemistry High 8780506
1997 Casein kinase II (CK2) phosphorylates FKBP52 at Thr-143 in the hinge I region both in vitro and in vivo; CK2-phosphorylated FKBP52 fails to bind hsp90, revealing phosphorylation as a mechanism to regulate chaperone complex composition. In vitro kinase assay with purified CK2, deletion mutant mapping, [32P] in vivo labeling, hsp90 binding assay Proceedings of the National Academy of Sciences of the United States of America High 9405642
1998 The TPR domain of FKBP52 requires appropriate downstream C-terminal sequences for hsp90 binding; unlike FKBP51, FKBP52's TPR domain does not require specific C-terminal sequences beyond the core TPR for hsp90 binding. FKBP52 and FKBP51 associate differentially with steroid receptors based on the TPR domain and poorly-conserved C-terminal sequences. Deletion mutant and chimera co-precipitation with hsp90, steroid receptor association assays Molecular endocrinology High 9514152
1998 Hsp90 C-terminal EEVD motif is critical for interaction with TPR cochaperones including FKBP52; p23 binding maps to the N-terminal ATP-binding domain of Hsp90; deletion of Hsp90 residues 661–677 abolishes dimerization and reduces all accessory protein interactions. Co-precipitation of Hsp90 mutants with cochaperones including FKBP52 Cell stress & chaperones Medium 9672247
1999 FKBP52 has one binding site per hsp90 dimer (cross-linking). The PPIase domain of FKBP52 mediates binding to cytoplasmic dynein (competed by PPIase fragment, not TPR fragment). FKBP52 also binds directly to the hsp90-free glucocorticoid receptor via a region distinct from both the PPIase and TPR domains. Chemical cross-linking of purified proteins, co-immunoadsorption from reticulocyte lysate, competitive inhibition with domain fragments The Journal of biological chemistry High 10601253
2000 FKBP52 interacts with interferon regulatory factor-4 (IRF-4), inhibiting IRF-4–PU.1 binding to the immunoglobulin light chain enhancer and IRF-4–PU.1 transactivation; this inhibition requires functional PPIase activity of FKBP52 and induces a detectable structural modification of IRF-4. Co-immunoprecipitation, transcriptional reporter assay, partial proteolysis analysis, PPIase-inactive mutant Immunity Medium 10714679
2001 The PPIase domain of FKBP52 links the GR-hsp90 heterocomplex to cytoplasmic dynein and is required for hormone-induced retrograde transport of the GFP-GR along microtubules to the nucleus; FKBP12 overexpression does not affect GFP-GR movement. Cotransfection with PPIase domain fragment, live-cell GFP-GR imaging, colcemid microtubule disruption, co-immunoadsorption from cytosol The Journal of biological chemistry High 11278753
2001 Hormone binding to the GR induces substitution of FKBP51 by FKBP52 in the GR-hsp90 heterocomplex and concomitant recruitment of dynein, while hsp90 remains; the resulting GR-hsp90-FKBP52-dynein complex translocates from cytoplasm to nucleus before complex dissociation and conversion to DNA-binding form. Immunofluorescence, subcellular fractionation, co-immunoprecipitation in hormone-treated cells The Journal of biological chemistry High 11751894
2001 FKBP52 chaperone activity resides in the C-terminal region (amino acids 264–400, domain 3, which overlaps with the TPR domain), while PPIase activity is confined to domain 1 (amino acids 1–148); the chaperone and hsp90-binding regions within domain 3 are distinct. Domain fragment expression, PPIase assay, chaperone aggregation assay, competition with Hsp90 C-terminal peptide The Journal of biological chemistry High 11473108
2001 In the yeast model, FKBP52 is the only immunophilin that potentiates GR hormone-dependent transactivation (up to 20-fold at limiting hormone); this requires both Hsp90-binding ability and PPIase activity of FKBP52, and works by increasing GR hormone-binding affinity. Saccharomyces cerevisiae reporter gene assay, FKBP52 mutant analysis (PPIase-dead and TPR-dead mutants) The EMBO journal High 12606580
2001 FKBP52 (dFKBP59) interacts directly with Drosophila TRPL Ca2+-permeable channels and with the scaffold protein INAD; expression of dFKBP59 inhibits Ca2+ influx through TRPL channels; mutations of conserved proline residues in TRPL (P702Q, P709Q) abolish interaction with dFKBP59. Yeast two-hybrid, co-immunoprecipitation in Sf9 and fly cells, electrophysiology (inside-out patch), fura-2 Ca2+ assay, site-directed mutagenesis The Journal of biological chemistry High 11514552
2001 Two PPIase monomers bind to one Hsp90 dimer; FKBP52 has the strongest affinity for Hsp90 among the three mammalian large PPIases (vs. FKBP51 and CyP40); catalytic prolyl isomerase activity of FKBP52 corresponds to that of the small immunophilin FKBP12. In vitro binding assay with purified proteins, enzymatic PPIase assay Journal of molecular biology Medium 11350175
2002 Crystal structure of the N-terminal FK506-binding domain of human FKBP52 (residues 1–140) solved at 2.4 Å; reveals six-stranded antiparallel beta-sheet plus alpha-helix similar to FKBP12; Pro120 and Lys121 explain reduced FK506 affinity and inability to activate calcineurin compared with FKBP12. X-ray crystallography, molecular replacement Acta crystallographica. Section D, Biological crystallography High 12499534
2003 C-terminal sequences outside the core TPR domain (residues ~400–420 and the final 30 amino acids) of FKBP51 and FKBP52 differentially regulate hsp90 binding; the final 30 residues of FKBP51 enhance hsp90 binding while the corresponding region of FKBP52 moderates it. Truncation mutant and chimera co-immunoprecipitation with Hsp90 The Journal of biological chemistry Medium 12611898
2004 FKBP52 PPIase domain I directly interacts with the copper metallochaperone Atox1; the interaction is enhanced by copper supplementation and decreased by copper chelation; FKBP52 overexpression increases rapid copper efflux in cells, implicating it in the copper efflux machinery. Yeast two-hybrid, GST pulldown, co-immunoprecipitation, 64Cu efflux assay The Journal of biological chemistry Medium 15133031
2005 FKBP52 is a critical cochaperone for progesterone receptor (PR) in the uterus; Fkbp52-knockout female mice show complete implantation failure due to reduced P4 binding to PR, attenuated PR transcriptional activity, and down-regulation of P4-regulated genes—demonstrating tissue-specific regulation of hormone action. Fkbp52 knockout mice, hormone binding assay, PR transcriptional reporter, gene expression analysis, uterine fractionation Proceedings of the National Academy of Sciences of the United States of America High 16176985
2005 FKBP52 is required for androgen receptor (AR) signaling in specific male reproductive tissues; FKBP52 is a component of AR complexes and enhances AR-mediated transactivation in a manner requiring both PPIase activity and Hsp90-binding ability; FKBP52 can restore function of a minimally active AR point mutant. Fkbp52 knockout mice, yeast and mammalian cell reporter assays, FKBP52 mutant analysis, co-IP of AR complexes Molecular endocrinology High 15831525
2005 FKBP52 inhibits TRPV5 channel activity via its PPIase domain; FKBP52 co-localizes with and specifically interacts with TRPV5 in the distal nephron; PPIase-inactive mutant of FKBP52 loses the inhibitory effect on TRPV5. Co-immunoprecipitation, 45Ca2+ uptake, patch-clamp electrophysiology, PPIase domain mutant, siRNA knockdown American journal of physiology. Renal physiology High 16352746
2006 FKBP52 facilitates intracellular trafficking of AAV vectors toward the nucleus via interaction with dynein; FKBP52-knockout MEFs show impaired nuclear accumulation of AAV genomes that is restored upon FKBP52 re-expression; intact AAV particles interact with both FKBP52 and dynein. Knockout MEF cells, self-complementary AAV transduction, nuclear fractionation, co-immunoprecipitation, FKBP52 rescue expression Virology Medium 16828834
2006 Fkbp52 knockout specifically reduces AR transcriptional activity in mouse embryonic fibroblasts; chromatin immunoprecipitation shows normal AR occupancy at gene promoters in knockout cells, indicating FKBP52 controls a downstream step in AR transactivation rather than DNA binding. Fkbp52 knockout mouse, mouse embryonic fibroblasts, reporter assays, chromatin immunoprecipitation, hormone binding assay The Journal of biological chemistry High 17142810
2007 The FK1 domain loop residue Pro119 (vs. Leu119 in FKBP51) is the critical determinant distinguishing FKBP52's ability to potentiate steroid receptor activity from FKBP51; PPIase catalytic activity is NOT required for potentiation, as PPIase-dead mutants still potentiate; the proline-rich loop overhanging the catalytic pocket is the functionally important receptor-interaction surface. Yeast genetic screen of randomly mutated FKBP51, site-directed mutagenesis, mammalian cell reporter assay Molecular and cellular biology High 17938211
2007 FKBP52 directly and specifically binds tubulin; the TPR-containing region (aa 267–400) is required for tubulin binding; a C-terminal sequence (aa 375–458) is necessary and sufficient for microtubule depolymerization activity; FKBP52 prevents tubulin polymerization in vitro. Direct binding assay with purified proteins, domain deletion analysis, tubulin polymerization assay, co-localization in PC12 cells, siRNA knockdown FASEB journal High 17435176
2009 FKBP52 links the mineralocorticoid receptor (MR)-hsp90 complex to dynein/dynactin motors for cytoplasmic-to-nuclear transport; replacement of FKBP52 by FKBP51 or TPR peptide favors cytoplasmic MR retention; the intact MR-hsp90 heterocomplex transits the nuclear pore undissociated. Immunofluorescence, fractionation, cross-linking of MR-hsp90 complexes, microtubule stabilization/reassembly assay on stripped MR immune pellets Molecular and cellular biology High 20038533
2009 FKBP52 mediates stimulus-dependent gating of TRPC1 channels via cis/trans isomerization of proline residues in TRPC1; this is required for chemotropic turning of neuronal growth cones to netrin-1 and for netrin-1/DCC-dependent midline axon guidance in the spinal cord. FKBP12 mediates spontaneous (not stimulus-dependent) TRPC1 opening. Biochemical PPIase assay on TRPC1 peptides, dominant-negative FKBP52 expression, axon guidance assays in vitro and in vivo (mouse spinal cord) Neuron High 19945390
2010 FKBP52 binds directly and specifically to Tau (preferentially its hyperphosphorylated form); FKBP52 antagonizes Tau-mediated microtubule assembly; FKBP52 overexpression in differentiated PC12 cells reduces neurite length and decreases Tau accumulation. Direct binding assay with purified proteins, microtubule assembly assay, co-localization in cortical neurons, PC12 overexpression, quantitative neurite length measurement Proceedings of the National Academy of Sciences of the United States of America High 20133804
2011 FKBP52 favors nuclear retention of RelA/NF-κB, enhances its association with DNA consensus sequences, and increases NF-κB transcriptional activity; these effects require FKBP52 PPIase activity and TPR domain but not Hsp90 interaction. Upon stimulation, NF-κB complex exchanges FKBP51 for FKBP52 (analogous to steroid receptor switching). FKBP52 is functionally recruited to promoters of NF-κB target genes. Reporter gene assay, Co-IP with purified proteins, EMSA, ChIP, siRNA knockdown The Journal of biological chemistry High 25104352
2011 Hsp90 can simultaneously accommodate FKBP52 and HOP, forming stable Hsp90(2)-FKBP52(1)-HOP(2) and Hsp90(2)-FKBP52(1)-p23(2)-HOP(2) complexes. Co-immunoprecipitation, dynamic light scattering, electron microscopy Oncotarget Medium 21378414
2011 MJC13, a small molecule inhibitor, blocks FKBP52-enhanced AR function by preventing hormone-dependent dissociation of the Hsp90-FKBP52-AR complex, leading to less hormone-bound receptor in the nucleus and inhibiting AR-dependent gene expression and prostate cancer cell proliferation. Yeast reporter assay screen, co-immunoprecipitation, nuclear fractionation, qPCR of AR target genes, cell proliferation assay Proceedings of the National Academy of Sciences of the United States of America High 21730179
2013 FKBP52 (FKBP52/Fkbp4) physically associates with Argonaute2 (hAgo2); FK506 treatment or siRNA depletion of Fkbp4/5 decreases Ago2 protein levels and impairs miRNA-mediated silencing; FKBP4 overexpression promotes miRNA-mediated Ago2 stabilization; unloaded Ago2 accumulates in FK506-treated cells. Co-immunoprecipitation (FKBP4-hAgo2), siRNA depletion, FK506 pharmacological inhibition, lysosome inhibitor rescue, miRNA reporter assay RNA (New York, N.Y.) Medium 24049110
2013 FKBP4 (FKBP52) and p23 form a stable complex with hAgo2 and are required for efficient RNAi/RISC loading; the interaction occurs before small RNA loading and in the cytoplasm; depletion of FKBP4 or pharmacological disruption with FK506 reduces Ago2 levels and impairs RNAi. Co-immunoprecipitation, siRNA depletion, FK506 treatment, luciferase reporter silencing assay Molecular biology of the cell Medium 23741051
2014 FKBP52 directly interacts with Tau-P301L (pathological mutant) and induces formation of Tau-P301L oligomers and filaments in vitro; FKBP52 knockdown in Tau-P301L transgenic zebrafish rescues defective axonal outgrowth and branching, and reduces pT181 phospho-Tau. Direct binding assay, EM analysis of oligomers/filaments, zebrafish Tau-P301L transgenic model with FKBP52 knockdown Proceedings of the National Academy of Sciences of the United States of America High 24623856
2014 The FK1 domain of FKBP52 physically interacts with the glucocorticoid receptor (GR) as demonstrated by bimolecular fluorescence complementation and proximity ligation assays; this interaction is part of the FKBP52-dependent suppression of TDO expression in glioblastoma cells. Bimolecular fluorescence complementation, in situ proximity ligation assay, siRNA knockdown of FKBP52, TDO activity assay Glia Medium 25132599
2015 FKBP52 induces aggregation of Tau-F4 fragment (Ser208–Ser324) into oligomers and filaments with prion-like seeding capacity; FKBP52-induced Tau-F4 oligomers can transfer conformational changes to full-length Tau in cells and seed aggregation of endogenous Tau in neuroblastoma cells. Light-scattering assay, blue native PAGE, electron microscopy, microtubule assembly assay, seeding in SH-SY5Y cells FASEB journal High 25888602
2016 FKBP52 links the hTERT-Hsp90 complex to the dynein-dynactin motor via binding of the TPR domain to Hsp90 and the PPIase domain to dynamitin (Dyt); FKBP52 depletion inhibits hTERT nuclear transport and causes cytoplasmic accumulation and ubiquitin-dependent degradation of hTERT, abrogating telomerase activity. Co-immunoprecipitation, siRNA knockdown, nuclear/cytoplasmic fractionation, telomerase activity assay, dynamitin overexpression The Biochemical journal Medium 27503910
2016 FKBP52's capacity to oligomerize Tau is independent of its PPIase catalytic activity (PPIase-dead mutant still oligomerizes Tau); the PHF6 peptide of Tau interacts with FK1/FK2 domains of FKBP52 independently of FK506 binding, identifying a non-catalytic interaction governing Tau oligomerization. In vitro oligomerization assay with PPIase-dead mutant, NMR interaction mapping, PPIase activity assay on Tau peptides Journal of molecular biology High 26903089
2019 FKBP4 is a proximal interacting protein of PI3K, Akt, and mTOR components; FKBP4 depletion specifically reduces cell growth and proliferation of triple-negative breast cancer cells; FKBP4 can enhance Akt activation through PDK1 and mTORC2. BirA proximity-dependent biotin identification (BioID) proteomics, siRNA knockdown, xenograft tumor model, cell proliferation assay Theranostics Medium 31660083
2021 FKBP4 promotes IKK complex assembly by interacting with both Hsp90 and IKK subunits (TPR domain required for Hsp90/IKK interaction, PPIase domain for IKKγ interaction), potentiating IKK kinase activity; FKBP4 also forms a complex with Hsp70/RelA to promote RelA nuclear translocation, activating NF-κB signaling in lung adenocarcinoma. Co-immunoprecipitation, domain deletion mutants, IKK kinase activity assay, nuclear fractionation, siRNA knockdown, xenograft Cell death & disease Medium 34112753
2021 FKBP52 overexpression in wild-type mouse hippocampus promotes phosphorylation of AD-relevant tau species, activates gliosis, and causes neuronal loss; FKBP52 overexpression (not Aha1) impairs spatial reversal learning in aged mice. AAV-mediated overexpression in mouse hippocampus, histological analysis, behavioral testing, immunohistochemistry for phospho-tau Acta neuropathologica communications Medium 33832539
2021 Both FKBP51 and FKBP52 are required for AR dimer formation and chromatin binding; depletion of either reduces AR phosphorylation; PPIase activity of FKBP51 is specifically required for AR dimerization; MJC13 (FKBP52-AR inhibitor) also inhibits AR dimer formation. siRNA depletion, AR dimerization assay, chromatin immunoprecipitation, phosphorylation analysis, FK506/MJC13 pharmacological inhibition Molecular oncology Medium 34057812
2022 FKBP52 interacts with BRCA1 and stabilizes estrogen receptor α (ERα) protein; FKBP52 depletion decreases ERα expression and breast cancer cell proliferation; FKBP51 reduces ERα stability in an opposing manner. Co-immunoprecipitation (FKBP52-BRCA1), siRNA knockdown, ERα protein stability assay, cell proliferation assay Proceedings of the National Academy of Sciences of the United States of America Medium 35394865
1995 FKBP52 (FKBP59-HBI) localizes to cytoplasm, nucleus, and partially co-localizes with microtubules in interphase non-lymphoid cells; during mitosis it segregates from chromosomes and associates with the mitotic apparatus (centrosome, spindle, interzone, cleavage furrow, midbodies). Indirect immunofluorescence confocal microscopy, Western blot of subcellular fractions, cytoskeletal drug treatment (taxol, nocodazole) Journal of cell science Medium 7544801
1996 FAP48 is a novel 48-kDa protein that specifically interacts with the immunosuppressant-binding domain (domain I) of FKBP52 (FKBP59) and also with FKBP12 but not CyP40; this interaction is prevented by FK506 and rapamycin in a dose-dependent manner, suggesting FAP48 shares the macrolide-binding site on FKBP52. Yeast two-hybrid, in vitro direct interaction assay, in vivo co-immunoprecipitation, FK506/rapamycin competition The Journal of biological chemistry Medium 8955134
2010 FKBP52 forms stable complexes with amyloid precursor protein (APP) through its FK506-interacting domain; FKBP52 overexpression reduces Abeta toxicity and increases lifespan in Abeta transgenic Drosophila; FKBP52 loss-of-function exacerbates Abeta phenotypes; FKBP52 interacts with Atox1 (copper transporter) and modulates intracellular copper levels, which influence Abeta pathology. Co-immunoprecipitation (FKBP52-APP), Drosophila transgenic gain/loss-of-function, copper chelator diet, intracellular copper measurement, cell reconstitution PloS one Medium 20084280
2010 FKBP52 interaction with RET51 tyrosine kinase receptor is triggered by GDNF and NGF activation of RET51; phosphorylation of RET51 tyrosine 905 is required for complex formation; disruption of this phosphorylation site abolishes the RET51/FKBP52 complex. Co-immunoprecipitation, RET51 mutagenesis (Y905 mutation), growth factor stimulation assay Human molecular genetics Medium 20442138
2012 FKBP52 localizes to the endolysosomal system in neurons and co-localizes with TRPC1 and Orai1 channels in human platelets; FKBP52 interaction with TRPC1 and IP3RII is required for maintenance of store-operated Ca2+ entry (SOCE); FK506/rapamycin reduce TRPC1-FKBP52 and TRPC1-IP3RII association, impairing SOCE. Immunoprecipitation, siRNA knockdown, Mn2+ entry assay, single-cell Ca2+ imaging, fura-2 Ca2+ measurement Biochimica et biophysica acta Medium 23228564
2020 The neuroregenerative effects of FK506 in vivo are mediated specifically by FKBP52; Fkbp52-knockout mice fail to show FK506-induced locomotor recovery after spinal cord injury, while Fkbp51-knockout mice respond normally; FKBP51 binding of FK506 antagonizes FKBP52-mediated neurotrophic action. Fkbp52 and Fkbp51 knockout mice, spinal cord injury model, FK506 treatment, behavioral assessment of locomotion Biochemical pharmacology High 32828804

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2001 A new first step in activation of steroid receptors: hormone-induced switching of FKBP51 and FKBP52 immunophilins. The Journal of biological chemistry 350 11751894
2003 The Hsp90-binding peptidylprolyl isomerase FKBP52 potentiates glucocorticoid signaling in vivo. The EMBO journal 296 12606580
1992 Expression and characterization of human FKBP52, an immunophilin that associates with the 90-kDa heat shock protein and is a component of steroid receptor complexes. Proceedings of the National Academy of Sciences of the United States of America 253 1279700
2011 FKBP51 and FKBP52 in signaling and disease. Trends in endocrinology and metabolism: TEM 217 21889356
2001 Evidence that the peptidylprolyl isomerase domain of the hsp90-binding immunophilin FKBP52 is involved in both dynein interaction and glucocorticoid receptor movement to the nucleus. The Journal of biological chemistry 200 11278753
2005 Cochaperone immunophilin FKBP52 is critical to uterine receptivity for embryo implantation. Proceedings of the National Academy of Sciences of the United States of America 189 16176985
2005 Physiological role for the cochaperone FKBP52 in androgen receptor signaling. Molecular endocrinology (Baltimore, Md.) 172 15831525
1998 Analysis of FKBP51/FKBP52 chimeras and mutants for Hsp90 binding and association with progesterone receptor complexes. Molecular endocrinology (Baltimore, Md.) 167 9514152
1994 The ability of the immunophilin FKBP59-HBI to interact with the 90-kDa heat shock protein is encoded by its tetratricopeptide repeat domain. Proceedings of the National Academy of Sciences of the United States of America 160 7526392
1993 The cyclophilin component of the unactivated estrogen receptor contains a tetratricopeptide repeat domain and shares identity with p59 (FKBP59). The Journal of biological chemistry 160 8514757
1996 Cyclophilin 40 (CyP-40), mapping of its hsp90 binding domain and evidence that FKBP52 competes with CyP-40 for hsp90 binding. The Journal of biological chemistry 159 8621687
1999 Different regions of the immunophilin FKBP52 determine its association with the glucocorticoid receptor, hsp90, and cytoplasmic dynein. The Journal of biological chemistry 158 10601253
2001 Functional analysis of the Hsp90-associated human peptidyl prolyl cis/trans isomerases FKBP51, FKBP52 and Cyp40. Journal of molecular biology 155 11350175
1998 Differential interactions of p23 and the TPR-containing proteins Hop, Cyp40, FKBP52 and FKBP51 with Hsp90 mutants. Cell stress & chaperones 151 9672247
2007 Noncatalytic role of the FKBP52 peptidyl-prolyl isomerase domain in the regulation of steroid hormone signaling. Molecular and cellular biology 134 17938211
2006 Essential role for Co-chaperone Fkbp52 but not Fkbp51 in androgen receptor-mediated signaling and physiology. The Journal of biological chemistry 127 17142810
2009 The hsp90-FKBP52 complex links the mineralocorticoid receptor to motor proteins and persists bound to the receptor in early nuclear events. Molecular and cellular biology 118 20038533
2011 Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America 112 21730179
2005 FKBP52. The international journal of biochemistry & cell biology 107 15381148
2010 A role for FKBP52 in Tau protein function. Proceedings of the National Academy of Sciences of the United States of America 104 20133804
2007 FKBP52 deficiency-conferred uterine progesterone resistance is genetic background and pregnancy stage specific. The Journal of clinical investigation 103 17571166
1997 Phosphorylation of the immunosuppressant FK506-binding protein FKBP52 by casein kinase II: regulation of HSP90-binding activity of FKBP52. Proceedings of the National Academy of Sciences of the United States of America 102 9405642
2009 Modulation of glucocorticoid receptor nuclear translocation in neurons by immunophilins FKBP51 and FKBP52: implications for major depressive disorder. Brain research 99 19545546
2007 Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities. Proceedings of the National Academy of Sciences of the United States of America 95 18162540
2014 NF-κB transcriptional activity is modulated by FK506-binding proteins FKBP51 and FKBP52: a role for peptidyl-prolyl isomerase activity. The Journal of biological chemistry 85 25104352
2004 Proteomic analysis identifies immunophilin FK506 binding protein 4 (FKBP52) as a downstream target of Hoxa10 in the periimplantation mouse uterus. Molecular endocrinology (Baltimore, Md.) 82 15528267
2019 Biological Actions of the Hsp90-binding Immunophilins FKBP51 and FKBP52. Biomolecules 79 30717249
1999 FK506 and the role of the immunophilin FKBP-52 in nerve regeneration. Drug metabolism reviews 78 10461545
2003 C-terminal sequences outside the tetratricopeptide repeat domain of FKBP51 and FKBP52 cause differential binding to Hsp90. The Journal of biological chemistry 76 12611898
2000 Posttranslational regulation of IRF-4 activity by the immunophilin FKBP52. Immunity 76 10714679
2007 The immunophilin FKBP52 specifically binds to tubulin and prevents microtubule formation. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 75 17435176
1993 Overexpression of p59-HBI (FKBP59), full length and domains, and characterization of PPlase activity. Biochemical and biophysical research communications 75 8216288
2017 Progesterone Resistance in Endometriosis Is Modulated by the Altered Expression of MicroRNA-29c and FKBP4. The Journal of clinical endocrinology and metabolism 73 27778641
1992 Rabbit FKBP59-heat shock protein binding immunophillin (HBI) is a calmodulin binding protein. Biochemical and biophysical research communications 72 1384470
2009 Peptidyl-prolyl isomerase FKBP52 controls chemotropic guidance of neuronal growth cones via regulation of TRPC1 channel opening. Neuron 66 19945390
2011 Regulation of steroid hormone receptor function by the 52-kDa FK506-binding protein (FKBP52). Current opinion in pharmacology 64 21511531
1999 Expression of the estrogen receptor-associated immunophilins, cyclophilin 40 and FKBP52, in breast cancer. Breast cancer research and treatment 64 10718488
1996 FAP48, a new protein that forms specific complexes with both immunophilins FKBP59 and FKBP12. Prevention by the immunosuppressant drugs FK506 and rapamycin. The Journal of biological chemistry 63 8955134
2019 FKBP4 connects mTORC2 and PI3K to activate the PDK1/Akt-dependent cell proliferation signaling in breast cancer. Theranostics 62 31660083
2009 Differential expression of immunophilins FKBP51 and FKBP52 in the frontal cortex of HIV-infected patients with major depressive disorder. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 62 19199039
2001 Estradiol-regulated expression of the immunophilins cyclophilin 40 and FKBP52 in MCF-7 breast cancer cells. Biochemical and biophysical research communications 62 11374893
2008 Deficiency of immunophilin FKBP52 promotes endometriosis. The American journal of pathology 60 18988805
2014 Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway. Glia 57 25132599
2006 Role of cellular FKBP52 protein in intracellular trafficking of recombinant adeno-associated virus 2 vectors. Virology 57 16828834
2014 Immunophilin FKBP52 induces Tau-P301L filamentous assembly in vitro and modulates its activity in a model of tauopathy. Proceedings of the National Academy of Sciences of the United States of America 55 24623856
2011 Organization and function of the FKBP52 and FKBP51 genes. Current opinion in pharmacology 54 21514887
2010 Uterine FK506-binding protein 52 (FKBP52)-peroxiredoxin-6 (PRDX6) signaling protects pregnancy from overt oxidative stress. Proceedings of the National Academy of Sciences of the United States of America 52 20713718
1995 The 59 kDa FK506-binding protein, a 90 kDa heat shock protein binding immunophilin (FKBP59-HBI), is associated with the nucleus, the cytoskeleton and mitotic apparatus. Journal of cell science 52 7544801
2013 Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression. Steroids 49 23380368
2012 FKBP4 is regulated by HOXA10 during decidualization and in endometriosis. Reproduction (Cambridge, England) 48 22279148
2010 Control of Alzheimer's amyloid beta toxicity by the high molecular weight immunophilin FKBP52 and copper homeostasis in Drosophila. PloS one 48 20084280
2001 Localization of the chaperone domain of FKBP52. The Journal of biological chemistry 48 11473108
2001 Regulation of Drosophila TRPL channels by immunophilin FKBP59. The Journal of biological chemistry 48 11514552
1997 Immunosuppressor binding to the immunophilin FKBP59 affects the local structural dynamics of a surface beta-strand: time-resolved fluorescence study. Biochemistry 48 9200682
2012 The neuroregenerative mechanism mediated by the Hsp90-binding immunophilin FKBP52 resembles the early steps of neuronal differentiation. British journal of pharmacology 47 22091865
2021 Hsp90 co-chaperones, FKBP52 and Aha1, promote tau pathogenesis in aged wild-type mice. Acta neuropathologica communications 46 33832539
1996 Three-dimensional structure of the immunophilin-like domain of FKBP59 in solution. Biochemistry 46 8780506
2022 Naringenin Regulates FKBP4/NR3C1/NRF2 Axis in Autophagy and Proliferation of Breast Cancer and Differentiation and Maturation of Dendritic Cell. Frontiers in immunology 42 35087512
2021 FKBP4 integrates FKBP4/Hsp90/IKK with FKBP4/Hsp70/RelA complex to promote lung adenocarcinoma progression via IKK/NF-κB signaling. Cell death & disease 42 34112753
2015 The FK506-binding protein FKBP52 in vitro induces aggregation of truncated Tau forms with prion-like behavior. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 38 25888602
2010 Fkbp52 regulates androgen receptor transactivation activity and male urethra morphogenesis. The Journal of biological chemistry 36 20605780
1997 The unliganded mineralocorticoid receptor is associated with heat shock proteins 70 and 90 and the immunophilin FKBP-52. Receptors & signal transduction 36 9392437
2013 The co-chaperones Fkbp4/5 control Argonaute2 expression and facilitate RISC assembly. RNA (New York, N.Y.) 35 24049110
2005 The immunophilin FKBP52 inhibits the activity of the epithelial Ca2+ channel TRPV5. American journal of physiology. Renal physiology 35 16352746
2012 Fkbp52 heterozygosity alters behavioral, endocrine and neurogenetic parameters under basal and chronic stress conditions in mice. Psychoneuroendocrinology 34 22641006
2011 Hsp90 can accommodate the simultaneous binding of the FKBP52 and HOP proteins. Oncotarget 33 21378414
2008 Targeted ablation reveals a novel role of FKBP52 in gene-specific regulation of glucocorticoid receptor transcriptional activity. The Journal of steroid biochemistry and molecular biology 33 19073255
2012 Decrease of the immunophilin FKBP52 accumulation in human brains of Alzheimer's disease and FTDP-17. Journal of Alzheimer's disease : JAD 32 22233767
2017 Molecular dynamics simulation, binding free energy calculation and unbinding pathway analysis on selectivity difference between FKBP51 and FKBP52: Insight into the molecular mechanism of isoform selectivity. Proteins 31 29023988
2015 Therapeutic Targeting of the FKBP52 Co-Chaperone in Steroid Hormone Receptor-Regulated Physiology and Disease. Current molecular pharmacology 31 25986565
2013 Hsp90 cochaperones p23 and FKBP4 physically interact with hAgo2 and activate RNA interference-mediated silencing in mammalian cells. Molecular biology of the cell 31 23741051
2004 A novel role for the immunophilin FKBP52 in copper transport. The Journal of biological chemistry 30 15133031
2002 Structure of the N-terminal domain of human FKBP52. Acta crystallographica. Section D, Biological crystallography 30 12499534
2021 FKBP51 and FKBP52 regulate androgen receptor dimerization and proliferation in prostate cancer cells. Molecular oncology 29 34057812
2021 KDM5D inhibits the transcriptional activation of FKBP4 by suppressing the expression of E2F1 in colorectal cancer in males. Biochemical pharmacology 28 34688635
2016 Hsp90-binding immunophilin FKBP52 modulates telomerase activity by promoting the cytoplasmic retrotransport of hTERT. The Biochemical journal 27 27503910
2020 FKBP4 Accelerates Malignant Progression of Non-Small-Cell Lung Cancer by Activating the Akt/mTOR Signaling Pathway. Analytical cellular pathology (Amsterdam) 26 33354489
2014 Differential conformational dynamics in the closely homologous FK506-binding domains of FKBP51 and FKBP52. The Biochemical journal 26 24749623
1993 Overexpression, characterization, and purification of a recombinant mouse immunophilin FKBP-52 and identification of an associated phosphoprotein. Proceedings of the National Academy of Sciences of the United States of America 26 8341706
2016 Caspase-cleaved Tau-D(421) is colocalized with the immunophilin FKBP52 in the autophagy-endolysosomal system of Alzheimer's disease neurons. Neurobiology of aging 25 27479154
2007 Deficiency of co-chaperone immunophilin FKBP52 compromises sperm fertilizing capacity. Reproduction (Cambridge, England) 25 17307907
2022 FKBP52 and FKBP51 differentially regulate the stability of estrogen receptor in breast cancer. Proceedings of the National Academy of Sciences of the United States of America 24 35394865
2018 Expression of FKBP52 in the ovaries of PCOS rats. International journal of molecular medicine 24 30483787
2012 FKBP52 is involved in the regulation of SOCE channels in the human platelets and MEG 01 cells. Biochimica et biophysica acta 23 23228564
2003 Organization of the human FK506-binding immunophilin FKBP52 protein gene (FKBP4). Genomics 22 12782134
2020 Peptidylprolylisomerases, Protein Folders, or Scaffolders? The Example of FKBP51 and FKBP52. BioEssays : news and reviews in molecular, cellular and developmental biology 21 32323357
2014 Analysis of FK506, timcodar (VX-853) and FKBP51 and FKBP52 chaperones in control of glucocorticoid receptor activity and phosphorylation. Pharmacology research & perspectives 21 25505617
2010 The RET51/FKBP52 complex and its involvement in Parkinson disease. Human molecular genetics 21 20442138
2020 FKBP4 is a malignant indicator in luminal A subtype of breast cancer. Journal of Cancer 20 32194784
2019 Regulation of FKBP51 and FKBP52 functions by post-translational modifications. Biochemical Society transactions 20 31754722
2023 Melatonin-mediated FKBP4 downregulation protects against stress-induced neuronal mitochondria dysfunctions by blocking nuclear translocation of GR. Cell death & disease 19 36810730
2016 Isomerization and Oligomerization of Truncated and Mutated Tau Forms by FKBP52 are Independent Processes. Journal of molecular biology 19 26903089
2021 Decrease of neuronal FKBP4/FKBP52 modulates perinuclear lysosomal positioning and MAPT/Tau behavior during MAPT/Tau-induced proteotoxic stress. Autophagy 18 33459145
2020 Proof that the high molecular weight immunophilin FKBP52 mediates the in vivo neuroregenerative effect of the macrolide FK506. Biochemical pharmacology 18 32828804
2018 Delineation of human prostate cancer evolution identifies chromothripsis as a polyclonal event and FKBP4 as a potential driver of castration resistance. The Journal of pathology 18 29484655
2010 Correlation of major depressive disorder symptoms with FKBP5 but not FKBP4 expression in human immunodeficiency virus-infected individuals. Journal of neurovirology 18 20726698
2014 Molecular chaperone activity and biological regulatory actions of the TPR-domain immunophilins FKBP51 and FKBP52. Current protein & peptide science 17 24694367
2020 Associations of FKBP4 and FKBP5 gene polymorphisms with disease susceptibility, glucocorticoid efficacy, anxiety, depression, and health-related quality of life in systemic lupus erythematosus patients. Clinical rheumatology 16 32557257
2012 Galectin-1 markedly reduces the incidence of resorptions in mice missing immunophilin FKBP52. Endocrinology 16 22416080
2007 Studies of a co-chaperone of the androgen receptor, FKBP52, as candidate for hypospadias. Reproductive biology and endocrinology : RB&E 16 17343741

Missed literature

Know a paper Affinage missed for FKBP4? Flag it for the maintainers and the community.

No submissions yet.